

ICMJE DISCLOSURE FORM

Date: 2/8/24

Your Name: Alexander I. Salter

Manuscript Title: Novel immunotherapy combinations in neoadjuvant NSCLC: a better chance at cure?

Manuscript number (if known): TLCR-23-735

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	Lyell Immunopharma	Patient licensing fees were paid to my previous institution, Fred Hutch Cancer Center, and are distributed to me on a yearly basis. Patents relate to cellular immunotherapy for cancer.
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	Lyell Immunopharma	See above
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

The author has multiple patents related to cancer immunotherapy, some of which have been licensed to Lyell Immunopharma.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 11/8/2023

Your Name: Millie Das

Manuscript Title: Novel immunotherapy combinations in neoadjuvant NSCLC: a better chance at cure?

Manuscript number (if known): TLCR-23-735

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	Merck: current Genentech: current CellSight: current Novartis: ended May 2023 Varian: ended Dec 2023 Verily: ended Dec 2021	Research funding paid to institution
3	Royalties or licenses	None	
4	Consulting fees	Eurofins Abbvie Janssen	
5	Payment or honoraria for lectures, presentations,	Plexus: Dec 2023 IDEO: March 2022	

	speakers bureaus, manuscript writing or educational events	Springer: Sept 2021 Medical Educator Consortium: Aug 2023 Dedham Group: Feb 2022 DAVA Oncology: June 2023 MJH Healthcare Holdings: Aug 2023 ANCO: ongoing Aptitude Health: Sept 2023 Med Learning Group: July 2023 Curio: Sept 2023 Triptych Health: Oct 2023	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	American Association of Clinical Oncology (ASCO)	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Advarra IRB DSMB Member Advisory boards: Sanofi/Genzyme: 5/24/23 Regeneron: 9/18/23 Janssen: 4/20/22 Astra Zeneca: 9/23/22 Gilead: 7/26/23 Guardant: 11/2023 Bristol Myer Squibb: 8/9/23, 9/20/23 Catalyst Pharmaceuticals: 9/10/23 Novocure: 10/14/23	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Association of Northern California Oncologists (ANCO), elected President	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Please summarize the above conflict of interest in the following box:

The author has participated in advisory boards for Advarra, Astra Zeneca, Bristol Myer Squibb, Catalyst Pharmaceuticals, Gilead, Guardant, Janssen, Novocure, Regeneron, Genzyme and Sanofi; has provided consulting services for Eurofins, Abbvie, and Janssen; has received institutional grant funding from Merck, Genentech, CellSight, Novartis, Varian, and Verily; is the President of the Association of Northern California Oncologists; and has received travel funds and honoraria for speaking at various meetings related to cancer immunotherapy (Plexus, IDEO, Springer, Medical Educator Consortium, Dedham Group, DAVA Oncology, MJH Healthcare Holdings, ANCO, Aptitude Health, Med Learning Group, Curio, and Triptych Health).

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.